- Conditions
- Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia
- Interventions
- SB497115, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 380
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Follicular Lymphoma
- Interventions
- Ibrutinib Oral Capsule, Placebo, Rituximab
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 25
- States / cities
- Mobile, Alabama • Duarte, California • Santa Barbara, California + 21 more
- Conditions
- Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Interventions
- Benralizumab Arm A, Benralizumab Arm B, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 138
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 114 more
- Conditions
- Schizophrenia
- Interventions
- Placebo, Lu AF11167
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Generalized Lipodystrophy
- Interventions
- Mibavademab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Dallas, Texas
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
- Interventions
- Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), Nab-paclitaxel
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more
- Conditions
- Healthy
- Interventions
- Gabapentin, Diphenhydramine citrate, Triazolam, Placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 4
- States / cities
- South Miami, Florida • Atlanta, Georgia
- Conditions
- Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
- Interventions
- Panzyga, 10% Intravenous Solution, Placebo
- Drug · Other
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Glendale, Arizona • Mesa, Arizona • Scottsdale, Arizona + 3 more
- Conditions
- Obesity and Cardiovascular Risk
- Interventions
- Oral BGE-102, Oral Placebo Matching BGE-102
- Drug
- Lead sponsor
- BioAge Labs, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 13 more
- Conditions
- Chronic Hepatitis B Virus Infection, Hepatitis B
- Interventions
- Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more
- Conditions
- Type 2 Diabetes
- Interventions
- icovamenib 100 mg, Placebo
- Drug
- Lead sponsor
- Biomea Fusion Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Canoga Park, California • Long Beach, California + 14 more
- Conditions
- Breast Cancer, Mindfulness
- Interventions
- Mindfulness Arm, Control group placebo
- Behavioral · Other
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 20 Years to 85 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Healthy Volunteers
- Interventions
- BMS-986533, Famotidine, Placebo, Dabigatran Etexilate, Rosuvastatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Arthritis, Rheumatoid
- Interventions
- CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg, Placebo, Methotrexate
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 8
- States / cities
- Aventura, Florida • Lexington, Kentucky • Frederick, Maryland + 5 more
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 38
- States / cities
- Chula Vista, California • La Jolla, California • Lancaster, California + 34 more
- Conditions
- Autoimmune Hepatitis
- Interventions
- VAY736, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 4
- States / cities
- Coronado, California • Rialto, California • Sacramento, California + 1 more
- Conditions
- Diabetic Kidney Disease
- Interventions
- BMS-813160, Placebo matching with BMS-813160
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- Not listed
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
- Conditions
- Sleep Disturbance, Sleep Quality
- Interventions
- 2 mg THC + 2 mg CBN + 2 mg CBG + 10 mg CBD + 1 mg Melatonin, 10 mg THC + 5 mg CBN + 5 mg CBG + 20 mg CBD, 10 mg THC + 20 mg CBN + 5 mg CBG, Stay Asleep Placebo, Fast Asleep Placebo
- Dietary Supplement
- Lead sponsor
- Cannabis Science Innovations, LLC
- Industry
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 332 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Sarasota, Florida
- Conditions
- Chronic Severe Plaque-type Psoriasis
- Interventions
- Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Osteoarthritis of Knee
- Interventions
- MM-II dose I, MM-II dose II, MM-II dose III, Placebo
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Riverside, California + 15 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo
- Biological · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 876 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2038
- U.S. locations
- 24
- States / cities
- Sacramento, California • Aurora, Colorado • New Haven, Connecticut + 20 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- CHF10067, Placebo
- Drug · Other
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Dothan, Alabama • St. Petersburg, Florida • Hannibal, Missouri + 3 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab 10 mg/kg, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more
- Conditions
- Prurigo Nodularis
- Interventions
- Rocatinlimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 18 more